Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia–Pacific Region: A Review and Multidisciplinary Expert Opinion

SIMPLE SUMMARY: For years, the systemic therapies sorafenib and lenvatinib have represented standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). The recent approval of atezolizumab in combination with bevacizumab heralded the arrival of immunotherapy for first-line t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogasawara, Sadahisa, Choo, Su-Pin, Li, Jiang-Tao, Yoo, Changhoon, Wang, Bruce, Lee, Dee, Chow, Pierce K. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197840/
https://www.ncbi.nlm.nih.gov/pubmed/34071818
http://dx.doi.org/10.3390/cancers13112626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197840/
https://www.ncbi.nlm.nih.gov/pubmed/34071818
http://dx.doi.org/10.3390/cancers13112626

Ejemplares similares